

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934
(Amendment No.)*

Novus Therapeutics, Inc.
(Name of Issuer)

Common Stock, par value \$0.001 per share
(Title of Class of Securities)

67011N105
(CUSIP Number)

March 9, 2018
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No 67011N105

1. NAME OF REPORTING PERSONS

LifeSci Venture Partners I, LP

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

(a)

(b)

3. SEC USE ONLY

4. CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

5. SOLE VOTING POWER

0

6. SHARED VOTING POWER

499,100

7. SOLE DISPOSITIVE POWER

0

8. SHARED DISPOSITIVE POWER

499,100

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

499,100

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

5.31%

12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

PN

CUSIP No 67011N105

1. NAME OF REPORTING PERSONS

LifeSci Venture SPV VII, LLC

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

(a)

(b)

3. SEC USE ONLY

4. CITIZENSHIP OR PLACE OF ORGANIZATION

New York

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

5. SOLE VOTING POWER

0

6. SHARED VOTING POWER

566,967

7. SOLE DISPOSITIVE POWER

0

8. SHARED DISPOSITIVE POWER

566,967

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

566,967

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

6.03%

12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

OO

CUSIP No 67011N105

1. NAME OF REPORTING PERSONS

LifeSci Index Partners, LLC

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

(a)

(b)

3. SEC USE ONLY

4. CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

5. SOLE VOTING POWER

0

6. SHARED VOTING POWER

1,066,067

7. SOLE DISPOSITIVE POWER

0

8. SHARED DISPOSITIVE POWER

1,066,067

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

1,066,067

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

11.33%

12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

IA

CUSIP No 67011N105

1. NAME OF REPORTING PERSONS

Andrew I. McDonald

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

(a)

(b)

3. SEC USE ONLY

4. CITIZENSHIP OR PLACE OF ORGANIZATION

United States of America

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

5. SOLE VOTING POWER

85,021

6. SHARED VOTING POWER

1,066,067

7. SOLE DISPOSITIVE POWER

85,021

8. SHARED DISPOSITIVE POWER

1,066,067

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

1,151,088

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

12.24%

12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
IN

CUSIP No 67011N105

Item 1. (a). Name of Issuer:
Novus Therapeutics, Inc.

(b). Address of Issuer's Principal Executive Offices:
19900 MacArthur Blvd., Suite 550
Irvine, CA 92612

Item 2. (a). Name of Person Filing:
LifeSci Venture Partners I, LP
LifeSci Venture SPV VII, LLC
LifeSci Index Partners, LLC
Andrew I. McDonald

(b). Address of Principal Business Office, or if None, Residence:
LifeSci Venture Partners I, LP
c/o LifeSci Venture GP, LLC
250 West 55th Street, 16th Floor
New York, NY 10019

LifeSci Venture SPV VII, LLC
c/o LifeSci Venture GP, LLC
250 West 55th Street, 16th Floor
New York, NY 10019

LifeSci Index Partners, LLC
250 West 55th Street, 16th Floor
New York, NY 10019

Andrew I. McDonald
c/o LifeSci Venture GP, LLC
250 West 55th Street, 16th Floor
New York, NY 10019

(c). Citizenship:
LifeSci Venture Partners I, LP – Delaware limited partnership
LifeSci Venture SPV VII, LLC – New York limited liability company
LifeSci Index Partners, LLC – Delaware limited liability company
Andrew I. McDonald – United States citizen

(d). Title of Class of Securities:
Common Stock, par value \$0.001 per share

(e). CUSIP Number:
67011N105

Item 3. If This Statement is filed pursuant to ss.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a

- (a) Broker or dealer registered under Section 15 of the Exchange Act (15 U.S.C. 78c).
- (b) Bank as defined in Section 3(a)(6) of the Exchange Act (15 U.S.C. 78c).
- (c) Insurance company as defined in Section 3(a)(19) of the Exchange Act (15 U.S.C. 78c).
- (d) Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
- (e) An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
- (f) An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
- (g) A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
- (h) A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);
- (i) A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j) Group, in accordance with s.240.13d-1(b)(1)(ii)(J).

Item 4. Ownership.

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a) Amount beneficially owned:

499,100 shares deemed beneficially owned by LifeSci Venture Partners I, LP
566,967 shares deemed beneficially owned by LifeSci Venture SPV VII, LLC
1,066,067 shares deemed beneficially owned by LifeSci Index Partners, LLC
1,151,088 shares deemed beneficially owned by Andrew I. McDonald

(b) Percent of class:

5.31% deemed beneficially owned by LifeSci Venture Partners I, LP
6.03% deemed beneficially owned by LifeSci Venture SPV VII, LLC
11.33% deemed beneficially owned by LifeSci Index Partners, LLC
12.24% deemed beneficially owned by Andrew I. McDonald

(c) Number of shares as to which LifeSci Venture Partners I, LP has:

(i)	Sole power to vote or to direct the vote	0 ,
(ii)	Shared power to vote or to direct the vote	499,100 ,
(iii)	Sole power to dispose or to direct the disposition of	0 ,
(iv)	Shared power to dispose or to direct the disposition of	499,100 .

Number of shares as to which LifeSci Venture SPV VII, LLC has:

(i)	Sole power to vote or to direct the vote	<u>0</u> ,
(ii)	Shared power to vote or to direct the vote	<u>566,967</u> ,
(iii)	Sole power to dispose or to direct the disposition of	<u>0</u> ,
(iv)	Shared power to dispose or to direct the disposition of	<u>566,967</u> .

Number of shares as to which LifeSci Index Partners, LLC has:

(i)	Sole power to vote or to direct the vote	<u>0</u> ,
(ii)	Shared power to vote or to direct the vote	<u>1,066,067</u> ,
(iii)	Sole power to dispose or to direct the disposition of	<u>0</u> ,
(iv)	Shared power to dispose or to direct the disposition of	<u>1,066,067</u> .

Number of shares as to which Andrew I. McDonald has:

(i)	Sole power to vote or to direct the vote	<u>85,021</u> ,
(ii)	Shared power to vote or to direct the vote	<u>1,066,067</u> ,
(iii)	Sole power to dispose or to direct the disposition of	<u>85,021</u> ,
(iv)	Shared power to dispose or to direct the disposition of	<u>1,066,067</u> .

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following .

Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.

N/A

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.

N/A

Item 8. Identification and Classification of Members of the Group.

If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.

N/A

Item 9. Notice of Dissolution of Group.

Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.

N/A

Item 10. Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

AGREEMENT

The undersigned agree that this Schedule 13G dated March 13, 2018 relating to the Common Stock, par value \$0.001 per share of Novus Therapeutics, Inc., shall be filed on behalf of the undersigned.

LIFESCI VENTURE PARTNERS I, LP

By: LifeSci Venture GP, LLC, its General Partner

By: /s/ Paul Yook

Name: Paul Yook

Title: Mnaging Member

LIFESCI VENTURE SPV VII, LLC

By: LifeSci Venture GP, LLC, its General Partner

By: /s/ Paul Yook

Name: Paul Yook

Title: Managing Member

LIFESCI INDEX PARTNERS, LLC*

By: /s/ Paul Yook

Name: Paul Yook

ANDREW I. MCDONALD

By: /s/ Andrew I. McDonald

Name: Andrew I. McDonald

March 13, 2018